Last week, Teva, one of Israel’s largest companies and the world’s largest generic pharmaceuticals manufacturer, made an offer to buy its competitor Mylan for $40 billion. Mylan was publicly okay with the idea, but has not made any final declarations. One of the conditions for Teva’s deal was that Mylan forego its own attempt to buy Perrigo, another Israeli pharma company. Since then, Perrigo has turned down Mylan’s offer. So what will happen in this cat-and-mouse game of business mergers?
Steven Tepper, Senior Research Analyst of Pharma and Biotech at Migdal Capital Markets explains to host Niv Elis just what this gargantuan deal means.
